LONGEVA.

FOXO4-DRI: adverse events and evidence limits

FOXO4-DRI is a D-retro-inverso peptide studied in cell cultures and mice. Baar and colleagues assessed platelet counts before treatment and 30 days afterward. [1]

The authors’ tolerability description concerns those experimental conditions. These experiments provide no human adverse-reaction frequencies for administered FOXO4-DRI; selective action on senescent cells alone does not establish clinical safety. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Tolerability in the models (platelet counts monitored)Cell cultures and mice; platelet counts assessed before treatment and 30 days afterwardThe authors’ tolerability description concerns those experimental conditions; the experiments provide no human adverse-reaction frequencies[1]

References

  1. Baar MP, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, Bourgeois BRM, Stryeck S, Rijksen Y, van Willigenburg H, Feijtel DA, van der Pluijm I, Essers J, van Cappellen WA, van IJcken WF, Houtsmuller AB, Pothof J, de Bruin RWF, Madl T, Hoeijmakers JHJ, Campisi J, de Keizer PLJ. (2017). Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging https://doi.org/10.1016/j.cell.2017.02.031.